Patents Assigned to GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION
  • RNA METHYLTRANSFERASE INHIBITOR, SCREENING METHOD THEREFOR, ANTI-CANCER AGENT EFFICACY ASSESSMENT MARKER, AND KIT FOR EFFECTIVELY PREDICTING FTSJ1 INHIBITOR
    Publication number: 20230210834
    Abstract: An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided
    Type: Application
    Filed: August 26, 2020
    Publication date: July 6, 2023
    Applicants: National University Corporation Okayama University, General Incorporated Association Pharma Valley Project Supporting Organization, National University Corporation Kumamoto University
    Inventors: Atsushi FUJIMURA, Kengo INOUE, Takayuki ANDO, Yoshinobu ISHIKAWA, Kazuhito TOMIZAWA
  • IMMUNE CHECKPOINT INHIBITOR COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE
    Publication number: 20220218693
    Abstract: Provided is a method for using a STAT3 inhibitor which exhibits an excellent antitumor effect. An antitumor agent comprises a quinoline carboxamide derivative of formula (I) below or a salt thereof as an active ingredient, and is administered in combination with an immune checkpoint inhibitor. The antitumor agent is administered before the administration of the immune checkpoint inhibitor.
    Type: Application
    Filed: April 23, 2020
    Publication date: July 14, 2022
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION
    Inventors: Akira ASAI, Nao MIYOSHI, Daisuke MURAOKA, Naohisa OGO, Hiroyuki TAKAHASHI
  • CANCER COMBINATION THERAPY USING QUINOLINE CARBOXAMIDE DERIVATIVE
    Publication number: 20220008409
    Abstract: Provided is a method for using a STAT3 inhibitor having a high antitumor effect and little side effects. The antitumor agent comprises a combination of a quinoline carboxamide derivative of formula (I) below or a pharmacologically acceptable salt thereof with one or more cancer molecular target drugs selected from the group consisting of an ALK inhibitor, an EGFR inhibitor, a multi kinase inhibitor, a HER2/EGFR inhibitor, an mTOR inhibitor, a BRAF inhibitor, a MEK inhibitor and a BCR-ABL inhibitor, wherein R1, R2, R3, R4, R5 and R6 are the same or different, and each represent a hydrogen atom, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, COOR7 (wherein R7 represents a substituted or unsubstituted alkyl group), or OR8 (wherein R8 represents a substituted or unsubstituted alkyl group).
    Type: Application
    Filed: September 17, 2019
    Publication date: January 13, 2022
    Applicants: KABUSHIKI KAISHA YAKULT HONSHA, GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION
    Inventors: Akira ASAI, Momomi TSUGANE, Hiroaki KONISHI, Akiko YOSHINAGA, Hiroyuki TAKAHASHI, Takahiro IIJIMA
  • Agent for overcoming immunosuppression and use thereof
    Patent number: 11213538
    Abstract: To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 4, 2022
    Assignees: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Akira Asai, Naohisa Ogo, Daisuke Muraoka, Hiroshi Shiku, Naozumi Harada
  • AGENT FOR OVERCOMING IMMUNOSUPPRESSION AND USE THEREOF
    Publication number: 20190038645
    Abstract: To provide an agent for overcoming immunosuppression which can overcome immunosuppression by regulatory T cells. An agent for overcoming immunosuppression and an inhibitor of FOXP3 function containing an anthracycline antibiotic as an active ingredient.
    Type: Application
    Filed: February 15, 2017
    Publication date: February 7, 2019
    Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, KABUSHIKI KAISHA YAKULT HONSHA
    Inventors: Akira ASAI, Naohisa OGO, Daisuke MURAOKA, Hiroshi SHIKU, Naozumi HARADA
  • 1,3,4-Oxadiazole-2-carboxamide compound
    Patent number: 8796320
    Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).
    Type: Grant
    Filed: December 28, 2010
    Date of Patent: August 5, 2014
    Assignees: General Incorporated Association Pharma Valley Project Supporting Organization, Pharma Design, Shizuoka Prefecture, Kumamoto Health Science University, Kabushiki Kaisha Yakult Honsha
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara
  • 1,3,4-OXADIAZOLE-2-CARBOXAMIDE COMPOUND
    Publication number: 20120302524
    Abstract: Provided is a 1,3,4-oxadiazole-2-carboxamide compound which has STAT3 inhibitory activity and is useful as an anticancer agent. Provided is a 1,3,4-oxadiazole-2-carboxamide compound represented by formula (I) or a pharmacologically acceptable salt thereof (in the formula, Ar represents a furyl group or the like; R1 represents a hydrogen atom or the like; and —X—Y represents a diaryl group such as a biphenyl group).
    Type: Application
    Filed: December 28, 2010
    Publication date: November 29, 2012
    Applicants: GENERAL INCORPORATED ASSOCIATION PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION, PHARMA DESIGN, INC., KABUSHIKI KAISHA YAKULT HONSHA, KUMAMOTO HEALTH SCIENCE UNIVERSITY, SHIZUOKA PREFECTURE
    Inventors: Akira Asai, Kenji Matsuno, Naohisa Ogo, Osamu Takahashi, Yoshiaki Masuda, Ayumu Muroya, Yasuto Akiyama, Tadashi Ashizawa, Tadashi Okawara